RESEARCH GRID / DOSE REGISTER
Tesamorelin dosage: the doses and routes studied in the literature
What was administered, to which population, by which route — a research-context register, not a human-use instruction.
The short version
This page reports the tesamorelin dosage figures that appear in published studies — what researchers gave, to whom, and how. It is not a how-to. The dose studied in the major trials was 2 mg injected under the skin once a day, used in HIV patients [1][2]. A lower 1 mg/day arm shows up in some secondary studies. The route was always subcutaneous (under the skin). Because this concerns research-grade material, no human-use dosing is recommended here — the figures are reported only as study facts.
Doses Studied in the Tesamorelin Literature
The extensively studied tesamorelin regimen is 2 mg subcutaneously once daily. That was the dose in the pivotal 26-week Phase 3 trial (n=412), where it reduced visceral fat 15.2% and raised IGF-1 81.0% [1], and in the 52-week program that sustained the visceral-fat reduction at roughly 18% [2]. The same 2 mg/day was used in the JAMA hepatic-fat trial, which produced a -42 cm2 visceral-fat treatment effect and a net -2.9% hepatic-fat reduction [3], and in the mechanistic study in 13 healthy men, where two weeks of dosing raised IGF-1 by 181 ug/L [4]. A lower 1 mg/day dose appears in secondary investigations as a comparison arm.
It is worth being exact about what "the studied dose" means. Across the program, 2 mg subcutaneously once daily is the figure attached to every pivotal efficacy result — the visceral-fat reduction, the IGF-1 elevation, the hepatic-fat change. The population pharmacokinetic work that characterized clearance spanned 1-2 mg/day [6]. These are doses administered to defined trial populations under medical supervision, reported here as study facts.
This page gives no human-use dosing instruction. The framing throughout is "studied at 2 mg/day subcutaneously in HIV patients," never a recommendation to self-administer. Research-grade tesamorelin supplied for laboratory use is not the approved finished drug product, and nothing here should be read as a dose to take.
Route studied
Every clinical trial used subcutaneous injection, typically at an abdominal site, and that is the only route examined in the human efficacy literature [1][2][3][4]. Preclinical work explored alternatives: in beagle dogs, intratracheal dry-powder delivery achieved 41% bioavailability relative to subcutaneous injection (13% absolute), with a comparable terminal half-life [9]. That inhaled route remains a preclinical curiosity, not a studied human regimen.
For the kinetics behind once-daily dosing — why a peptide that clears from plasma in minutes still works on a daily schedule — see the tesamorelin half-life page.
Why the regimen was once daily
The once-daily schedule reflects a pharmacokinetic-pharmacodynamic mismatch that is the central theme of the pharmacokinetics of tesamorelin. The parent peptide clears rapidly from plasma — population modeling estimated apparent clearance around 1,060 L/h [6] — but its downstream effect, raised growth hormone and then IGF-1, persists across the dosing interval. Population PK also found the absorbed fraction was roughly 13% higher by day 14 than day 1, with no clinically relevant demographic covariates affecting exposure [6]. Short plasma life, sustained biological effect: that is the rationale for once-daily administration documented in the research.
A population pharmacokinetic-pharmacodynamic model made the point directly, confirming that tesamorelin stimulates growth hormone in an episodic (pulsatile) manner and linking subcutaneous exposure to the GH and IGF-1 response [7]. The peptide fires the pituitary; the IGF-1 response then unfolds on a slower clock than the drug's own clearance. That decoupling is why a molecule with a half-life measured in minutes was dosed once a day rather than several times daily.
Handling and reconstitution in the literature
The trans-3-hexenoic acid N-terminal modification blocks the DPP-IV cleavage that rapidly inactivates native GHRH, giving the molecule its plasma stability [8]. The approved product is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before subcutaneous administration; published handling notes specify refrigerated storage and use of the reconstituted solution within a defined window [14]. Research-grade material handling follows laboratory protocols, not a self-administration regimen, and this page summarizes published handling notes for context only — it gives no human-use instruction.